Business / Finance

RSS

Drug research “innovation crisis” is a myth

The widely touted “innovation crisis” in pharmaceutical research is a myth, argue experts in an article published on bmj.com today.

8 Aug 2012

Healthcare Trust of America second quarter total revenues increase 12.0% to $76.3M

Healthcare Trust of America, Inc. announced results for the three months ended June 30, 2012.

8 Aug 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012.

7 Aug 2012

Astellas announces closure of Urogenix research facility

Astellas Pharma Inc. announced that it decided to close Urogenix, Inc., an Astellas subsidiary, which is a research facility focusing on drug discovery in the field of urology.

6 Aug 2012

Helix BioMedix second quarter revenue decreases 32% to $471,000

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012.

3 Aug 2012

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan Inc. today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations.

3 Aug 2012

Toshiba establishes Chinese Procurement Center in Shanghai

Toshiba Medical Systems Corporation has established the Chinese Procurement Center in Shanghai.

3 Aug 2012

Stemgent acquires Asterand’s Human Tissue Business for $9 million

Stemgent, Inc. announced today that it has completed the acquisition of Asterand Plc's Human Tissue Business for $9 million. Asterand provides a set of high quality, human-tissue based tools for drug and drug target discovery that is highly complementary to Stemgent's growing portfolio of innovative research products and services to advance cellular reprograming and stem cell research.

1 Aug 2012

Exactech second quarter revenue increases 7% to $55.2 million

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $55.2 million for the second quarter of 2012, a 7% increase over $51.7 million in the second quarter of 2011.

31 Jul 2012

Hyperion Therapeutics announces completion of initial public offering

Hyperion Therapeutics, Inc. announced today the completion of its initial public offering of 5,000,000 shares of common stock.

31 Jul 2012

Transcat first quarter net revenue decreases 2.0% to $25.1 million

Transcat, Inc., a leading distributor of professional grade handheld test, measurement and control instruments and accredited provider of calibration, repair, inspection and other compliance services, today reported financial results for its first quarter ended June 30, 2012.

31 Jul 2012

Oclaro fourth quarter revenues increase to $104.4 million

Oclaro, Inc., a provider of optical components, modules and subsystems, today announced the financial results for its fourth quarter and fiscal year 2012, which ended June 30, 2012.

31 Jul 2012

NYGC purchases four Life Technologies' Ion Proton Sequencers

Life Technologies Corporation today announced that the New York Genome Center (NYGC) has purchased four Ion Proton Sequencers for its new Innovation Center.

31 Jul 2012

Life Technologies second quarter revenue increases 1% to $950 million

Life Technologies Corporation today announced results for its second quarter ended June 30, 2012.

31 Jul 2012

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2012.

31 Jul 2012

Acadia second quarter revenue increases 58.1% to $100.5 million

Acadia Healthcare Company, Inc. today announced financial results for the second quarter ended June 30, 2012.

31 Jul 2012

Ventas prices public offering of $275 million of 3.25% Senior Notes due 2022

Ventas, Inc. announced today that it has priced a public offering of $275 million aggregate principal amount of 3.25% Senior Notes due 2022 at 99.027% of principal amount.

31 Jul 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

MEDNAX acquires Loudoun Anesthesia Associates

MEDNAX, Inc., today announced the acquisition of Loudoun Anesthesia Associates, a physician group practice that provides anesthesia services at Inova Loudoun Hospital and Inova Loudoun Ambulatory Surgery Center in Leesburg, Va.

31 Jul 2012

Aetna reports net income of $457.6 million for second-quarter 2012

Aetna today announced second-quarter 2012 operating earnings of $452.0 million, or $1.31 per share, compared to the $1.35 per share reported in the second quarter of 2011.

31 Jul 2012